Topical Targretin and Intralesional Interferon Alfa for Cutaneous Lymphoma of the Scalp

Trent, Jennifer T.

doi:10.1001/archderm.138.11.1421

Cited by 14 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one particular report, a 56-yearold male was diagnosed with a follicle center B-cell cutaneous lymphoma [37]. In one particular report, a 56-yearold male was diagnosed with a follicle center B-cell cutaneous lymphoma [37].…”

Section: Combination Therapymentioning

confidence: 99%

Bexarotene: a clinical review

Farol

Hymes

2004

Expert Review of Anticancer Therapy

115

View full text Add to dashboard Cite

Bexarotene (Targretin, Ligand Pharmaceuticals Inc.) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. Early clinical trials of this drug demonstrated activity in cutaneous T-cell lymphoma. Subsequent Phase II/III trials have demonstrated a greater than 50% response rate in patients with all stages of cutaneous T-cell lymphoma who were refractory or intolerant to the previous therapy. The principal toxicities of bexarotene include central hypothyroidism, xeroderma and elevation of cholesterol and triglycerides. These toxicities can be managed with dose attenuation or addition of atorvastatin (Lipitor, Pfizer) or fenofibrate (TriCor, Abbott Laboratories). Since bexarotene has little bone marrow toxicity, it is an excellent candidate for combination therapy with other modalities useful in the treatment of cutaneous T-cell lymphoma. These include ultraviolet B irradiation, psoralen and ultraviolet A photochemotherapy, interferons, denileukin diftitox (Ontak, Ligand Pharmaceuticals Inc.) and cytotoxic chemotherapy. Bexarotene has also been investigated in the treatment of breast cancer and non-small cell carcinoma of the lung with promising early results.

show abstract

Section: Combination Therapymentioning

confidence: 99%

Bexarotene: a clinical review

Farol

Hymes

2004

Expert Review of Anticancer Therapy

115

View full text Add to dashboard Cite

show abstract

“…There are case reports showing the efficacy of topical therapy with using steroids, imiquimod, and nitrogen mustard or bexarotene gel. 375,[383][384][385][386] For patients presenting with generalized disease, the guidelines have included observation, rituximab, topical therapy, local RT, intralesional steroids, or systemic therapy (chlorambucil or CVP) with or without rituximab as options. In patients with very extensive or symptomatic disease, other chemotherapy regimens recommended for the treatment of FL may be used.…”

Section: Nccn Recommendationsmentioning

confidence: 99%

Non-Hodgkin's Lymphomas

Zelenetz

Abramson

Advani

et al. 2011

J Natl Compr Canc Netw

164

View full text Add to dashboard Cite

OverviewNon-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B-, T-, or natural killer (NK) lymphocytes. In the United States, B-cell lymphomas represent 80% to 85% of the cases, with 15% to 20% being Tcell lymphomas; NK lymphomas are rare. In 2010, an estimated 65,540 new cases of NHL were diagnosed and 20,210 patients died of the disease.1 NHL is the sixth leading site of new cancer diagnoses among men and women, accounting for 4% of new cancer cases and 4% of cancer-related deaths.

show abstract

“…Similar to other topical retinoids, bexarotene induces local irritation in approximately 70% of treated patients, with most cases being mild to moderate in severity (36,37). The present authors have also used bexarotene gel to treat refractory skin tumors, and it is effective in combination with intralesional interferon (IFN) (43).…”

Section: Clinical Use Of Retinoids In Cutaneous T‐cell Lymphomamentioning

confidence: 99%

Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma

Zhang

Duvic

2003

Dermatol Ther

View full text Add to dashboard Cite

Retinoids, natural and synthetic derivatives of vitamin A, are biological regulators of differentiation, proliferation, apoptosis, and immune response. Retinoic-acid-receptor-selective retinoids (all-trans retinoic acid, 13-cis-retinoic acid, and the synthetic analogs isotretinoin, etretinate and acitretin) have been used for years as monotherapy and/or in combination for treatment of cutaneous T-cell lymphoma (CTCL). Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL. The topical gel formulation was also effective for early cutaneous manifestations of CTCL or as an adjunct to systemic or phototherapy. Bexarotene treatment induces apoptosis of CTCL cells with down-regulation of its receptors and of survivin, an inhibitor of apoptosis. Identification of new receptor subtype-selective retinoids, combination of various receptor-selective retinoids or other agents, and a new drug delivery system may improve the clinical efficacy of retinoids in the future.

show abstract

Topical Targretin and Intralesional Interferon Alfa for Cutaneous Lymphoma of the Scalp

Cited by 14 publications

References 15 publications

Bexarotene: a clinical review

Bexarotene: a clinical review

Non-Hodgkin's Lymphomas

Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma

Contact Info

Product

Resources

About